A cost analysis of upfront DPYD genotype –guided dose individualisation in fluoropyrimidine-based anticancer therapy

Fluoropyrimidine therapy including capecitabine or 5-fluorouracil can result in severe treatment-related toxicity in up to 30% of patients. Toxicity is often related to reduced activity of dihydropyrimidine dehydrogenase, the main metabolic fluoropyrimidine enzyme, primarily caused by genetic DPYD polymorphisms. In a large prospective study, it was concluded that upfront DPYD-guided dose individualisation is able to improve safety of fluoropyrimidine-based therapy. In our current analysis, we evaluated whether this strategy is cost saving.

https://www.ejcancer.com/article/S0959-8049(18)31473-4/fulltext?rss=yes

Source: European Journal of Cancer - December 11, 2018 Category: Cancer & Oncology Authors: Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man, Didier Meulendijks, Geert W.J. Frederix, Emma Kienhuis, Geert-Jan Creemers, Arnold Baars, Vincent O. Dezentj é, Alexander L.T. Imholz, Frank J.F. Jeurissen, Johanna E.A. Portielje, Rob L.H. Jans Tags: Original Research Source Type: research